TNF and myeloid sarcoma: Additionally, the assessment of the TNF-α (Figure 4B) and IL-1β (Figure 4C) concentrations in the plasma of MS patients represented higher levels in the MS patients (+626% and +152%, respectively) prior to antioxidant treatment compared to the healthy group.